BIOSTAR PHARM-B (02563) saw its shares plummet more than 37% intraday. At press time, the stock was down 29.98% to HK$3.55, with a turnover of HK$5.82 million. The sharp decline followed the expiration of its one-year listing lock-up period, releasing approximately 246 million restricted shares into the market.

In the first half of this year, BIOSTAR PHARM-B reported revenue of RMB14.79 million, down 55.36% year-on-year. Net losses narrowed by 23.41% to RMB54.04 million, with a basic loss per share of RMB0.15.